Diana F. Clarke, Pharm.D.
Assistant Professor
Boston University School of Medicine
Dept of Pediatrics
Infectious Diseases

PharmD, State University of New York at Buffalo

P1097A - TO# LDR 04 MOD 02 - Raltegravir Pharmacokinetics and Safety in Neonates
01/01/2014 - 12/31/2018 (PI)
Johns Hopkins University NIH-NIAID

P1110 - TO# LDR 02 MOD 03 - Phase I Trial (Merck)
01/01/2014 - 12/31/2018 (PI)
Johns Hopkins University NIH-NIAID

LOC-IMPAACT Leadership Group - JHU P1097 and P1110
01/01/2014 - 11/30/2015 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT Leadership Award: Chair, Protocol P1097
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT Leadership: Vice Chair Pharmacy Resource Committee
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT Leadership: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
06/01/2011 - 05/31/2012 (PI)
Social & Scientific Systems Inc. NIH-NIAID

IMPAACT Leadership - P1097 Protocol Chair
06/01/2011 - 05/31/2012 (PI)
Social & Scientific Systems Inc. NIH-NIAID

06/01/2010 - 05/31/2011 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):83-93.View Related Profiles. PMID: 29039686.
  2. Clarke DF, Yildirim I, Cooper ER. Rapid Initiation of Antiretrovirals in Two Newly Diagnosed HIV-infected Infants. Pediatr Infect Dis J. 2017 Jan; 36(1):61-62.View Related Profiles. PMID: 27749654.
  3. Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):310-5.View Related Profiles. PMID: 25162819; PMCID: PMC4197108; DOI: 10.1097/QAI.0000000000000316;.
  4. Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M. Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J. 2013 Sep; 32(9):978-80.View Related Profiles. PMID: 23470680; PMCID: PMC3856729; DOI: 10.1097/INF.0b013e31829044a8;.
  5. Mirochnick M, Clarke D. Oseltamivir pharmacokinetics in pregnancy: a commentary. Am J Obstet Gynecol. 2011 Jun; 204(6 Suppl 1):S94-5.View Related Profiles. PMID: 21640232; DOI: 10.1016/j.ajog.2011.02.043;.
  6. Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010 Dec; 37(4):907-27, xi.View Related Profiles. PMID: 21078458; DOI: 10.1016/j.clp.2010.08.006;.
  7. Mirochnick M, Clarke DF, McNamara ER, Cabral H. Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets. Am J Health Syst Pharm. 2000 Oct 1; 57(19):1775-7.View Related Profiles. PMID: 11030029.
  8. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000 Oct; 39(4):281-93.View Related Profiles. PMID: 11069214.
  9. Mirochnick M, Michaels M, Clarke D, Breña A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. J Pediatr. 1993 May; 122(5 Pt 1):806-9.View Related Profiles. PMID: 8496767.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2000 and 2017

Contact for Mentoring:

72 E. Concord St Instructional (L)
Boston MA 02118
Google Map

Clarke's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department